Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Neuronetics, Inc. (NASDAQ: STIM), a leading commercial-stage medical technology company specializing in neurohealth, has announced its participation at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The company’s management team will engage in a fireside chat at 12:30 p.m. ET, with the presentation available to registered attendees through the conference portal.

Neuronetics is dedicated to transforming mental health care by providing innovative treatment options. Its flagship product, the NeuroStar Advanced Therapy System, offers a non-drug, noninvasive solution for patients suffering from Major Depressive Disorder (MDD) and other mental health conditions, particularly when traditional medications fail. With over 7.4 million treatments delivered, NeuroStar is recognized as the leading Transcranial Magnetic Stimulation (TMS) therapy for MDD in adults, supported by the largest clinical database in TMS history.

In addition to providing the NeuroStar therapy system, Neuronetics operates Greenbrook TMS Inc., which manages numerous treatment centers across the United States. These centers not only facilitate the NeuroStar therapy but also administer SPRAVATO® (esketamine) Nasal Spray, an FDA-approved treatment for treatment-resistant depression (TRD) and acute suicidal ideation in adults. Greenbrook has successfully treated over 55,000 patients, delivering more than 1.8 million treatments.

The NeuroStar Advanced Therapy System is FDA-cleared for MDD in adults and adolescents aged 15-21, along with indications for obsessive-compulsive disorder and anxious depression. Neuronetics emphasizes the importance of mental health as equal to physical health, aiming to enhance the quality of life for patients globally. For more information, interested parties are encouraged to visit NeuroStar.com for safety information and treatment indications.

As Neuronetics, Inc. (NASDAQ: STIM) prepares to participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, investors should closely monitor its developments and strategic positioning within the neuroscience and mental health sectors. Neuronetics has established itself as a leader in non-invasive mental health treatments, particularly through its NeuroStar Advanced Therapy, which has been validated by substantial clinical data and is FDA-cleared for various applications.

The upcoming conference will provide an essential platform for Neuronetics’ management to communicate their vision, recent advancements, and potential growth strategies. Notably, the company operates Greenbrook TMS, a treatment center network that facilitates access to these innovative therapies, expanding its market reach significantly. With over 7.4 million NeuroStar treatments delivered and more than 1.8 million sessions administered using SPRAVATO, Neuronetics is poised to capture a larger market share in the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD).

Investors should consider the broader market dynamics, including increasing awareness and integration of mental health services into primary healthcare, which presents growth opportunities for Neuronetics. The company’s commitment to delivering comprehensive treatment options could enhance patient outcomes and lead to sustained revenue growth.

However, it's crucial to assess the competitive landscape and potential regulatory changes that may impact reimbursement rates or market access for TMS therapies. Attendees at the Piper Sandler conference will likely gain insight into how management views these challenges.

In summary, Neuronetics’ participation in the conference could offer valuable information that may impact its stock performance. Investors should remain attentive to how the company articulates its strategy to leverage its established product offerings while addressing market dynamics. Monitoring post-conference responses and any updates will be key for making informed investment decisions in this burgeoning sector.